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SAMA’s inward-looking approach to 
AIDS and ethics 
To the Editor: Posted together with the February issue of SAMJ 
was a copy of SAMA’s Human Rights and Ethical Guidelines on 
HIV and AIDS – A Manual for Medical Practitioners,1 updating 
the 2001 edition to reflect changes in the response to the AIDS 
epidemic in South Africa, notably the increasingly accessible 
antiretroviral therapy (ART) in the public sector. SAMA seems 
not to encourage wide dissemination of, and discussion on, its 
Guidelines. 
I moderate an online discussion forum on HIV Policy and 
Ethics for the Southern African HIV Clinicians Society. A recent 
case study concerned the thorny ethical issue of whether a 
surgeon with HIV/AIDS on ART had to disclose her HIV status 
to her patient after discovering blood on the inside of the first 
of her double gloves after surgery. I thought it appropriate 
to refer members of the discussion forum to the Health 
Professions Council of South Africa (HPCSA) Guidelines on 
The Management of Patients with HIV Infection or AIDS2 (which 
replaced the South African Medical and Dental Council 
(SAMDC) Guidelines of 1994) and SAMA’s new Guidelines. 
While the HPCSA Guidelines can be accessed, the latest SAMA 
Guidelines cannot be located on the Internet.  (The URL on the 
HPCSA website referring to their Guidelines (http://www.
hpcsa.co.za/hpcsa/UserFiles/File/Patient’sRightsCharter.
pdf ) did not function at the time of writing, but the Guidelines 
could be accessed from secondary sources such as http://
alp.org.za.dedi20a.your-server.co.za/images/upload/
3rdAids%20finalss%20append.pdf (last accessed 29 May 2007)).
I requested, from SAMA’s Human Rights, Law and Ethics 
Department and its Corporate Communications Department, 
an electronic copy of the Guidelines to post on the discussion 
forum website. I was informed that only SAMA members 
could access this on the SAMA website, while a hard copy was 
available in the SAMJ. Not being a SAMA member, a hard copy 
would cost R120, or alternatively R2 500 for an electronic copy 
that could be made available to special interest groups as a 
special concession from SAMA. 
SAMA’s position on its Guidelines is perplexing. In a 
devastating AIDS epidemic, it seems elementary that new 
knowledge, innovative ideas and technological advances are 
widely shared. While South Africa boasts an impressive legal 
framework, laws or policy have not adequately addressed 
every issue pertaining to HIV/AIDS. In lieu of law or policy, 
lawyers, AIDS organisations and medical practitioners are often 
guided by standards produced by medical and ethical bodies, 
which have invested skills and expertise in thinking through 
some of the complex implications of the epidemic, such as 
contained in SAMA’s latest Guidelines. It follows that it is in 
the public interest for such documents to be made generally 
available, and for their use to be encouraged and promoted.  
HIV/AIDS is not a purely medical issue, and for its 
devastating effects to be adequately contained, it is crucial 
that a wide range of expertise, resources, disciplines and skills 
are sourced. Restricting SAMA’s Guidelines to an exclusive 
group of members of the Association who are chiefly medical 
professionals, or to those who can purchase a copy, does an 
injustice to the Association’s approach and commitment to the 
epidemic. This seems petty and short-sighted, particularly as 
doctors and medical scientists debate whether it is ethical for 
access to new knowledge to be limited to paid-up subscribers 
of major medical journals.3-5 SAMA’s attitude harkens 
back, damagingly, to closed bureaucracies, institutional 
possessiveness and competitive small-mindedness. I therefore 
call on SAMA to seriously review its current position on 
restricting various documents and Guidelines to its members 
only, to make the HIV Guidelines freely available on the 
Internet, and to mail hard copies to all AIDS organisations and 
community-based organisations that may not have access to the 
Internet.
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Pap smears in the Third World
To the Editor: A 73-year-old woman presented to the 
emergency unit at Polokwane Hospital complaining of chronic 
abdominal pain. When asked whether she had visited a health 
professional before, she produced an old referral letter from a 
general practitioner which read: ‘It is not possible to do a Pap 
smear in a Third-World general practice.’
Cervical cancer is the commonest cause of cancer death 
among women in the developing world.1 It is the duty and 
responsibility of every primary health care doctor to be able to 
assess patients with cervical abnormalities. This is particularly 
important in developing countries where the incidence of 
cervical cancer is high, with 30 - 100/100 000 women acquiring 
the disease.1
One of the principles of family medicine is that every 
consultation should be used as an opportunity for health 
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promotion and prevention. Failing to do a Pap smear is 
inexcusable and negligent.
Sa’ad Lahri
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Glibenclamide – what dose?
To the Editor: Doses of a wide variety of pharmacological 
agents currently used in clinical practice differ from the doses 
initially recommended at the time of drug registration.1 Oral 
antidiabetic agents, in particular the sulphonylureas (SUs), so 
far lack this degree of post-approval evaluation. 
The low cost and ready availability of SUs to the state make it 
a popular agent in the management of type 2 diabetes mellitus.
Manufacturers of glibenclamide are inconsistent and even in 
conflict in their recommendations on the maximum dose. This 
discrepancy in dose recommendation among the manufacturers 
has resulted in inappropriate doses of glibenclamide being 
prescribed. 
An audit of the prescribing of glibenclamide at selected 
provincial institutions in KwaZulu-Natal showed that 25% 
of all dose unit packs dispensed comprised the 20 mg dose of 
glibenclamide (Table I).  
From this audit it is not possible to determine whether 
these doses are associated with efficacy or safety issues. High 
dosage appears to have been used by centres supplying 
medication mainly to geriatric patients. There is controversy 
as to whether there is a linear relationship between dose and 
pharmacodynamic response. Various studies have suggested 
that SUs may have efficacy below doses recommended by 
manufacturers and that doses above half of maximal do not 
add to clinical benefit.2-5 High-dose glibenclamide with its 
high potency and long duration of action carries the risk of 
prolonged hypoglycaemia, especially in the elderly and those 
with irregular eating habits. In addition, SUs may mask the 
severity of a myocardial infarction.6
While the cost of glibenclamide to the province is low because 
of the nature of the present tender system of purchase, it may 
become an issue if the single exit price for medicines from 
manufacturers is implemented. 
In conclusion, this survey of glibenclamide usage in the 
greater eThekwini/Durban area confirms that the maximum 
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Table I. Usage of 20 mg dose as inferred from number of pre-packed units of 112 glibenclamide tablets dispensed by provincial 
institutions in the greater eThekwini/Durban area in 2002/3
Centre  Number of 20 mg/day dose packs prepared in 2002 Total of all packs prepared in 2002 Percentage
A      5 694       23 116          25
B    28 334       64 743          44
C      3 083       44 415            7
D      3 594       15 230          24
E      6 590       14 758          45
F      2 621       38 750            7
Total    49 916     201 012          25
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